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Abstract
Objectives To assess the diagnostic accuracy of 64-
multidetector CT (MDCT) for restaging of patients with
oesophageal cancer undergoing neoadjuvant therapy.
Methods Results of pathological staging were correlated
with those from 64-MDCT before and after neoadjuvant
treatment in 35 patients using the American Joint Commit-
tee on Cancer/TNM classification (7th edition). CT response
was determined using the Response Evaluation Criteria in
Solid Tumours (RECIST) method, modified for one-
dimensional tumour diameter measurement.
Results 64-MDCT predicted T stage correctly in 34 %
(12/35), overstaged in 49 % (17/35) and understaged in
17 % (6/35). Sensitivity/specificity values were as follows:
T0, 20 %/92 %; T1–T2, 31 %/59 %; T3, 60 %/64 %; T4,
100 %/4 %. Negative predictive values for T3/T4 were
80 %/100 %. MDCT accurately predicted complete histo-
pathological response in 20 % (accuracy 74 %) and
overstaged in 80 %. Tumour regression grade was predicted
correctly in only 8 % (2/25) and underestimated in 68 %
(17/25). Accurate N stage was noted in 69 % (24/35).
Conclusion Although MDCT tends to be able to exclude
advanced tumour stages (T3, T4) with a higher likelihood,
the diagnostic accuracy of high resolution MDCT for
restaging oesophageal cancer and assessing the response to
neoadjuvant therapy has not improved in comparison to
older-generation CT. Therefore, the future assessment of
oesophageal tumour response should focus on combined
morphologic and metabolic imaging.
Key Points
• Multidetector CT (MDCT) has been beneficial for the
evaluation of many tumours.
• However diagnostic accuracy for restaging oesophageal
cancer has not improved with MDCT.
• MDCT tends to be able to exclude advanced tumour stages
(T3/T4).
• MDCT has a low accuracy for determining lymph node
metastasis.
• Oesophageal tumour response should be assessed by
combined morphological and metabolic imaging.
Keywords Oesophageal cancer . Multidetector-row
computed tomography . Neoadjuvant treatment . Tumour
staging . Multislice computed tomography
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Introduction
Latest cancer statistics confirm oesophageal cancer to be
among the 10 most common malignancies leading to death
[1]. The tumours are associated with a high mortality as
most tumours are at the time of diagnosis in an advanced
stage (T3/T4, N+, or M1) as a result of the late onset of
symptoms [1]. So far, surgery remains the main therapy in
curable oesophageal carcinoma [2]. By virtue of the poor
prognosis of locally advanced oesophageal tumours (T3/T4,
N+) with an overall 5-year-survival rate of 42 % after
exclusive oesophagectomy, neoadjuvant multimodal treat-
ments are frequently performed before surgery to induce
tumour regression and improve outcome [3–7]. Current
analysis shows that patients who respond to neoadjuvant
treatment have a markedly better prognosis after surgery
than non-responders [8, 9]. Meredith et al. [10] showed that
patients achieving a histopathological complete response
(CR) following neoadjuvant treatment had a 5-year disease
free survival and overall survival of 52 % and 52 %, respec-
tively, compared with 22 % and 19 % in non-responders. A
disease-specific 5-year-survival rate of even 68 % in com-
plete histological responders after multimodality treatment
was shown in a recent multicentre study [11]. The tumour
response in patients with squamous cell carcinoma to
neoadjuvant therapy may as well identify a group of patients
with good prognosis, regardless of whether surgery with a
high incidence of postoperative complications will be
performed or not [12], and there are intensive discussions
globally whether both responders and non-responders
should be referred to surgery [13, 14].
Identification of responders and non-responders to preop-
erative treatment is therefore of paramount importance for
prognosis of the individual patient with oesophageal cancer.
Imaging plays a crucial role in this task. Endoscopic ultra-
sound (EUS) has been shown to not accurately predict path-
ologic stage in patients with oesophageal cancer who have
received neoadjuvant treatment. Thus it should no longer be
routinely performed for restaging purposes [15, 16]. The most
commonly used imaging investigations to reassess patients for
resection after neoadjuvant treatment include computed to-
mography (CT) and positron emission with fluoro-2-
deoxyglucose (FDG-PET) preferably performed in a hybrid
fashion as PET/CT [2, 13, 14, 17–20]. Several studies have
shown that contrast-enhanced CT has limited diagnostic ac-
curacy for evaluation of therapeutic response. Using CT the
sensitivity/specificity values for assessment of tumour re-
sponse of patients with oesophageal cancer undergoing pre-
operative treatment range between 27–67 % and 33–93 %
[21–28]. However, when analysing these studies it has to be
pointed out that most were performed with single-slice CT
which is no longer state-of-the-art CT equipment. It may been
hypothesised that tumour response in patients with
oesophageal cancer can be more accurately assessed by
MDCT owing to its superior spatial resolution [28].
Therefore, the purpose of our study was to assess the
diagnostic accuracy of 64-row MDCT for restaging of pa-
tients with oesophageal cancer undergoing neoadjuvant
therapy.
Materials and methods
Patients
This retrospective study was approved by our institutional
review board, and a waiver of informed consent was
obtained. The study was performed in accordance with the
principles of the Declaration Helsinki [29]. We retrospec-
tively reviewed charts of 112 patients with biopsy-proven
oesophageal cancer who underwent a gastro-oesophageal
resection in our hospital between January 2004 and March
2012. Before surgery the clinical tumour stage of any of the
included patients was either T3 N0, T1 to T3 with N1 to N3
disease or T4 Nx without metastasis (M0) and the need for
neoadjuvant treatment was decided by the institutional
multidisciplinary tumour board after careful review of all
treatment options for the individual patient. Staging pro-
cedures before neoadjuvant treatment included endoscopy
with endoscopic ultrasonography with fine-needle aspira-
tion and FDG-PET preferably performed in a hybrid fashion
as PET/CT or multidetector CT of the chest and abdomen. A
staging laparoscopy for oesophageal tumours of the lower
third was optional.
For the current study the patients were only included if a
64-slice contrast-enhanced MDCTof the chest and abdomen
before and after neoadjuvant treatment was available for
review, whereas the time window between commencement
and termination of the neoadjuvant treatment and subse-
quent surgery should not have exceeded 8 weeks.
Preoperative combined radio-chemotherapy, chemotherapy
only, surgery and final patient population
Radio- and chemotherapy were planned in parallel for a
duration of 5 weeks. The gross tumour volume included
the primary tumour and regional lymph nodes. The clinical
target volume included areas at risk for microscopic disease
with a 5 cm cranial and caudal margin and a 2 cm lateral
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margin. A standard dose of 45–50.4 Gy in 25–28 fractions
of 1.8 Gy was applied [30]. Eighteen patients with adeno-
carcinoma and squamous cell carcinoma were additionally
treated with two courses of combination chemotherapy (5-
fluorouracil, cisplatin) as described in the literature [31, 32].
Four patients with adenocarcinoma and squamous cell car-
cinoma intravenously received two cycles of induction ther-
apy with cisplatin and docetaxel. In those patients,
chemoradiation started after the second induction chemo-
therapy cycle. For 5 weeks patients underwent radiotherapy
as described above and weekly concomitant intravenous
chemotherapy with cisplatin and docetaxel [30].
In 5 patients with adenocarcinoma and squamous cell car-
cinoma two cycles of induction chemoimmunotherapy with
cisplatin, docetaxel and cetuximab were given intravenously.
This treatment was followed by chemoimmunoradiation thera-
pywith a radiotherapy standard dose of 45Gy in 25 fractions of
1.8 Gy and concomitant chemotherapy administered on an
outpatient basis with a weekly dose of docetaxel, cisplatin
and cetuximab [33].
In 8 patients with adenocarcinoma of the oesophagogastric
junction (classified as Siewert I and II) [34], the perioperative
treatment consisted of combined chemotherapy with
epirubicin, cisplatin and 5-fluorouracil (ECF) only. ECF was
administered pre- and postoperatively, three cycles each [35].
Restaging with MDCT was performed 4–5 weeks after
completion of neoadjuvant therapy. Surgery was performed
6–8 weeks after completion of the neoadjuvant treatment.
Twenty-four patients underwent transthoracic oesophagectomy.
In 5 patients transhiatal oesophagectomy was performed. Six
patients were treated with total oesophagectomy.
Four patients did not undergo the entire regimen of
preoperative therapy and were therefore excluded from the
study. A contrast-enhanced 64-slice MDCT before and with-
in 6 weeks after termination of the neoadjuvant treatment
was unavailable for review in 73 patients.
The final study population consisted of 35 patients (mean
age, 60.4 years; range, 42–73 years) who underwent
neoadjuvant treatment with subsequent surgery. This group
included 26 men (mean age, 61.1 years; range, 46–70 years)
and 9 women (mean age, 58.4 years; range, 42–73 years).
The histopathological cell type was adenocarcinoma in 25
patients (71.4 %) and squamous cell carcinoma in 10 pa-
tients (28.6 %). In 8 patients the tumour arose from the
middle thoracic oesophagus. The lower thoracic oesophagus
was involved in 12 patients and the gastro-oesophageal
junction in 15 patients. Table 1 displays further specific
details of the patient population.
Histopathological analysis and response evaluation
The Mandard grading system was used to determine the histo-
pathological tumour regression in response to neoadjuvant
therapy as described in the literature [36]. The grading system
is based on the presence of histopathological regressive changes.
In grade 1 (complete regression) a specimen showed residual
fibrosis without histologically identifiable residual cancer. Grade
2 involved the presence of rare residual cancer cells scattered
through the fibrosis. Grade 3 showed an increase in the number
of residual cancer cells, but fibrotic tissue still predominated.
Grade 4 was characterised by residual cancer outgrowing fibro-
sis. Grade 5 showed cancer without regressive changes. Tumour
regression grade according toMandard et al. [36] was defined in
26 of the 35 patients in the pathologist’s report.
The results of the analysis of the surgical specimen
served as standard of reference.
CT protocol
All MDCT examinations of the chest and abdomen before
and after initiation of neoadjuvant preoperative treatment
were performed using 64-row MDCT (Lightspeed VCT
64; GE Healthcare, Milwaukee, Wis/USA).
Patient preparation included 500 mL of diluted oral con-
trast medium (Telebrix Gastro; Guerbet AG, Zurich, Swit-
zerland) followed by 30 g barium sulfate oesophageal cream
(E-Z-EM, Inc., Lake Success, NY/USA). Eighty to one
hundred millilitres of contrast material (Ultravist 300; Bayer
Schering Pharma, Berlin, Germany) was administered intra-
venously by a power injector at a rate of 2 mL/s followed by
a bolus of 40 mL saline solution with a 70-s delay (portal
venous phase). The thorax and abdomen were examined in
the cranio-caudal direction during the portal venous phase
(delay, 50–70 s). The following imaging parameters were
used: tube voltage, 120 kVp; tube current, 180 mAs
with automated modulation technique; section width,
1.25 mm (for a detector configuration 40×1.25 mm);
rotation time, 0.6 s; pitch, 1.375. For image reconstruc-
tion, a moderately smoothing convolution kernel (B30)
and a 512×512 pixel matrix was used. We reconstructed
axial images with a section width of 2 mm and an
increment of 1.0 mm. Coronal and sagittal reformations
were reconstructed using a standard CT workstation
with the section width of 2 mm.
Image evaluation
All MDCT data were interpreted in consensus by two
experienced radiologists with 15 years and 7 years of
experience in interpreting gastrointestinal CT imaging
using a picture archiving and communication system
workstation (PACS) (Impax 6.4; AGFA Healthcare,
Mortsel, Belgium). The two reviewers were blinded to
the lesion location, size, clinical and surgical findings as
well as the histopathological results. To ensure consis-
tency in the evaluation of the pre- and post-adjuvant
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therapy studies, data from both examinations were al-
ways analysed during the same reading session.
Measurements were performed using the electronic cal-
liper of the workstation.
Table 1 Patient characteristics, tumour histology, tumour location,
changes in MDCT T and N stage between pre- and post-neoadjuvant
therapy and comparison between post-therapy-MDCT and pathological
T and N staging; wall thickness changes between pre- and post-therapy
MDCT, CT-TRG after neoadjuvant therapy at MDCT and comparison
with P-TRG
Patient no./age
(years)
G H L T stage Wall thickness
(mm)
Response N stage
Pre-
CT
Post-
CT
P Pre-
CT
Post-
CT
CT-
TRG
P-
TRG
Pre-
CT
Post-
CT
P
1/62 M AC EJ T4a T4a T3 15 15 SD / N2 N2 N3
2/66 M SCC Mid T3 T1/T2 T0 11 7 SD CR N0 N0 N0
3/60 M AC Low T4a T3 T0 24 12 PR CR N1 N0 N0
4/65 M SCC Mid T4b T4b T0 15 11 SD CR N3 N1 N0
5/61 M AC Low T3 T3 T2 19 11 SD PR N1 N1 N0
6/42 F AC EJ T3 T3 T2 24 10 PR DP N1 N0 N0
7/52 M SCC EJ T1/T2 T3 T0 29 21 SD / N1 N0 N0
8/64 M AC EJ T3 T3 T2 27 14 SD / N2 N1 N2
9/57 M AC EJ T3 T3 T1 11 11 SD / N1 N1 N1
10/73 F SCC EJ T3 T3 T3 14 10 SD PR N0 N0 N0
11/47 M AC EJ T3 T3 T3 19 10 SD PR N1 N1 N0
12/61 M AC Low T3 T3 T1 13 10 SD PR N1 N1 N0
13/63 M SCC EJ T3 T1/T2 T0 10 7 SD / N0 N0 N0
14/62 M AC Mid T1/T2 T0 T2 7 3 CR / N1 N0 N1
15/54 F SCC EJ T3 T1/T2 T0 15 10 SD CR N1 N0 N0
16/50 M AC Low T1/T2 T1/T2 T0 9 8 SD CR N0 N0 N0
17/70 M AC EJ T3 T3 T3 20 12 SD DP N1 N1 N1
18/58 M AC EJ T3 T3 T3 12 12 SD SD N0 N0 N0
19/68 M AC Low T4a T3 T1 12 12 SD PR N2 N0 N0
20/60 M AC Low T3 T1/T2 T0 15 7 PR CR N0 N0 N0
21/49 F AC Low T3 T1/T2 T2 15 9 SD PR N0 N0 N0
22/52 F SCC Mid T3 T1/T2 T2 12 5 PR SD N0 N0 N0
23/61 F SCC Low T1/T2 T0 T0 8 4 CR / N0 N0 N0
24/61 F SCC Mid T1/T2 T1/T2 T3 9 6 SD DP N0 N0 N0
25/69 M AC Low T4a T3 T2 17 13 SD PR N1 N1 N0
26/68 M AC EJ T3 T0 T0 16 4 CR / N2 N0 N0
27/46 M AC EJ T4a T3 T3 23 23 SD PR N2 N0 N1
28/67 M AC Low T3 T3 T3 15 12 SD SD N1 N1 N1
29/67 M AC Mid T3 T1/T2 T3 11 6 SD DP N2 N1 N3
30/61 F AC Mid T3 T1/T2 T3 10 6 SD PR N0 N0 N0
31/63 M AC Low T1/T2 T1/T2 T1 9 8 SD PR N0 N0 N0
32/62 M SCC Mid T1/T2 T1/T2 T0 8 6 SD CR N1 N1 N1
33/73 F AC EJ T4a T1/T2 T1 13 8 SD DP N2 N0 N0
34/53 M AC Low T0 T0 T1 * * * DP N0 N3 N1
35/67 M AC EJ T4a T4a T4b 22 22 SD – N3 N3 N3
MDCT multidetector computed tomography, CT-TRG computed tomography tumour regression grade assessed by modified Eastern Cooperative
Oncology Group criteria, P-TRG pathological tumour regression grade according to Mandard et al. [36], G gender,M male, F female, H histology, AC
adenocarcinoma, SCC squamous cell carcinoma, L location, Up upper thoracic oesophagus, Mid middle thoracic oesophagus, Low lower thoracic
oesophagus, EJ, oesophagogastric junction, Pre-CT computed tomography before neoadjuvant therapy, Post-CT computed tomography after
neoadjuvant therapy, CT-TRG computed tomography tumour regression grade assessed by modified Eastern Cooperative Oncology Group criteria, P-
TRG pathological tumour regression grade according to Mandard et al. [36], P pathological findings, CT computed tomography, * no tumour visible on
CT, – no information in pathological report, CR complete response, PR partial response, SD stable disease, DP disease progression
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T staging
The tumour was staged by MDCT before and after
neoadjuvant therapy according to the 7th edition of the
AJCC/TNM classification [37–39]. The deepest tumour inva-
sion determined the main tumour location (cervical oesopha-
gus, upper thoracic oesophagus, middle thoracic oesophagus,
lower thoracic oesophagus/ oesophagogastric junction) [39].
To access the tumour depth we defined an oesophageal
wall thickness of equal to or wider than 5 mm as pathological
[22, 40–42]. Wall thickness was measured perpendicular to
the lumen of the oesophagus. If the lumen was not visible the
maximal transverse tumour diameter was obtained and multi-
plied by a factor of 0.5 [24]. The wall thickness was deter-
mined at the same tumour level in the preoperative follow-up
study as in the baseline examination [28].
By modifying the classification system of Tio et al. [43]
and Jones et al. [22] and consistent with the 7th TNM
edition [37–39] the according MDCT T status was defined
as follows: CT–T0: wall thickness less than 5 mm and
without signs of mediastinal involvement. The CT–T1 and
CT–T2 stages were combined because it was impossible to
differentiate between the oesophageal wall layers on MDCT
images. CT–T1 and CT–T2 stages were defined as having a
wall thickness of at least 5–10 mm without evidence of
mediastinal involvement. CT–T3 stage was defined when
the tumour exhibited a wall thickness of greater than 10 mm
with mediastinal involvement, but no invasion of adjacent
structures was present. A CT–T4a (invasion of pleura, peri-
cardium, diaphragm) and CT–T4b (invasion of other struc-
tures e.g. aorta, vertebral body, trachea) were defined if the
tumour had a wall thickness of greater than 10 mm and
invaded adjacent structures.
N staging
For N staging we included regional lymph nodes extending
from cervical perioesophageal to the celiac axis as described
in the 7th edition of the AJCC/TNM classification [37–39].
Lymph nodes were regarded to be positive for malignancy
with a short axis diameter of at least 10 mm [22, 43–45].
The N status using MDCT was staged as follows: N0
corresponded to no evidence of pathological regional lymph
nodes. Metastases in 1–2 regional lymph nodes were staged
as N1 and in 3–6 lymph nodes as N2. N3 was defined as
metastasis in at least 7 regional lymph nodes [37–39].
M staging
The M staging was described as Mx if distant organ metas-
tasis could not be assessed, M0 if no distant organ metasta-
sis was evident and as M1 if distant organ metastasis was
present [37–39].
CT response evaluation
To investigate the tumour response to neoadjuvant therapy
at MDCT we used the World Health Organisation
(WHO)/Response Evaluation Criteria in Solid Tumours
(RECIST) method [46], modified for one-dimensional mea-
surement, and correlated the results with the histopatholog-
ical tumour regression grade (TRG) as described by
Mandard et al. [22, 36]. Absence of tumour on post-
treatment MDCT was defined as complete response, corre-
lating with a TRG 1. A decrease of at least 50 % in tumour
diameter was described as partial response, correlating with
TRG 2. Stable disease matched the criteria of no increase or
decrease of less than 50 % or increase of less than 25 % of
tumour diameter, corresponding to a TRG 3. An increase of
at least 25 % in tumour diameter was defined as a disease
progression, being consistent with a TRG of 4 or 5.
Statistics
Statistical analysis was performed by using statistical software
(SPSS, version 17.0.1, SPSS, Chicago, Ill; Microsoft Excel
2010). Sensitivity, specificity, positive and negative predictive
value as well as accuracy were evaluated. Agreement between
histopathology and post-therapeutic T stage, histopathology
and post-therapeutic N stage or tumour regression grade, re-
spectively, was determined by calculating Cohen’s kappa
values for tumour status, nodal status and tumour regression
grade. A kappa value of less of 0.4 indicated poor to moderate
agreement, between 0.4 and less than 0.75 indicated fair to
good agreement and at least 0.75 indicated excellent agreement.
Results
The distribution of T and N stages among the patient pop-
ulation based on MDCT imaging and following histopatho-
logical analysis after surgery is displayed in Table 2.
None of the tumours involved the cervical or upper
thoracic oesophagus. The primary tumour was visible on
MDCT before commencement of the neoadjuvant treatment
Table 2 Histopathological T and N staging characteristics of study
population
T0 T1/T2 T3 T4 Total
N0 10 9 5 24
N1 1 3 3 7
N2 1 1
N3 2 1 3
Total 11 13 10 1 35
T tumour stage, N nodal stage
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Fig. 1 A 67-year-old, correctly staged patient with adenocarcinoma of
the lower thoracic oesophagus histopathological T3 N1 M0 disease. a
Axial, pre-neoadjuvant therapy, contrast-enhanced MDCT at the level
of the coronary sinus shows a circumferential oesophageal wall thick-
ening with obliteration of the lumen. The maximal transverse tumour
diameter was obtained and multiplied by a factor of 0.5. b Axial, post-
neoadjuvant therapy, contrast-enhanced MDCT image obtained at the
same level shows a small (<50 %) decrease in oesophageal wall
thickness. MDCT correctly predicted tumour regression grade as stable
disease and accordingly staged the tumour as T3
Fig. 2 A 61-year-old,
understaged patient with
histopathological T3 N0 M0
squamous cell carcinoma.
a Axial pre-neoadjuvant therapy,
contrast-enhanced MDCT shows
an oesophageal wall thickening
at the level of the left pulmonary
artery. b Sagittal reformatted
MDCT image shows focal dorsal
wall thickening of the middle
thoracic oesophagus, which was
regarded as the location of the
primary MDCT T1/2 tumour
(arrowhead). c Axial post-
neoadjuvant therapy, contrast-
enhanced MDCT obtained at the
same level shows a slight
decrease in oesophageal wall
thickening. d Sagittal
reformattedMDCT image shows
a decrease in focal dorsal wall
thickening (arrowhead), but the
oesophageal wall appears to be
generally thickened over a long
distance. MDCT misinterpreted
the findings as stable disease and
understaged the residual tumour
as T1/2. Histopathology even
showed disease progression and
a T3 tumour was found in the
surgical specimen
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in 34/35 (97 %) of cases. The tumour regression grade was
evaluated in 25 patients as the tumour was not visible on
MDCT in 1 of those 26 patients.
Prediction of post-therapeutic T stage
Overall the T stage was correctly predicted by 64-slice
MDCT in 12 of the 35 patients (34 %) (Fig. 1). Overstaging
occurred in 49 % (17/35) and understaging occurred in 17 %
(6/35) (Fig. 2). Table 3 shows the diagnostic performance of
64-slice MDCT according to tumour stage. The results dem-
onstrated high negative predictive values of 80 % and 100 %
for T3 and T4 disease. When comparing the results of the
pre- to the post-neoadjuvant therapy MDCT, the patients’ T
status was downstaged in 46 % (16/35) and upstaged in 3 %
(1/35). In one patient the tumour was not visible on MDCT.
The kappa value between histopathology and T stage was
poor (0.10).
Prediction tumour response
Ten of the 35 patients (28.6 %) showed a complete response
(ypT0N0) to neoadjuvant therapy on histopathology. Two of
those 10 patients (20 %) showed a complete response on
MDCT using our criteria with a sensitivity of 20 %, speci-
ficity of 96 %, positive predictive value of 67 %, negative
predictive value of 75 % and an accuracy of 74 % (Table 4).
64-slice MDCT overstaged 8 of the 10 complete patholog-
ical responders and predicted T1–T2 stage in 5, T3 disease
in 2 and T4 stage in 1 patient (Fig. 3). The tumour regres-
sion grade was predicted correctly by 64-slice MDCT in a
total of only 8 % (2 of 25 patients). The degree of regression
was overestimated in 24 % (6/25) and underestimated in
68 % (17/25) of patients. More specific information about
the regression grades for the 25 evaluated patients is listed in
Table 5. The kappa value between histopathology and tu-
mour regression grade was 0.01.
Prediction of post-therapeutic N stage
MDCT correctly staged the nodal disease in 69 % (24/35),
overstaged in 17 % (6/35) and understaged in 14 % (5/35) of
patients (Fig. 4). The efficacy of MDCT for the specific N
stages is shown in detail in Table 6. Referring to the pre- and
post-therapy MDCT the N stage was downstaged in 34 %
(12/35) and upstaged in 3 % (1/35). The kappa value be-
tween histopathology and post-therapeutic N stage was 0.4
Prediction of M stage
In none of the 35 patients was distant organ metastasis
found using MDCT data sets.
Discussion
With only 34 % of patients having the T stage of their
disease correctly predicted and 69 % having the N stage
accurately predicted, this study demonstrates that restaging
of oesophageal cancer after neoadjuvant therapy by high
resolution 64-slice MDCT did not improve in comparison
to single-slice CT. Therefore, the assumption made by some
authors that higher spatial resolution as provided by MDCT
technology will improve the diagnostic accuracy of MDCT
could not be confirmed [26, 27].
Our results revealed a diagnostic accuracy of 74 % using
64-row MDCT to predict complete pathological tumour
response, which is slightly higher as compared with
Table 3 Computed data and diagnostic performance of 64-MDCT for T staging
T n TP TN FP FN Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
T0 11 2 23 2 8 20 92 50 74 71
T1/T2 13 4 13 9 9 31 59 31 59 49
T3 10 6 16 9 4 60 64 40 80 63
T4* 1 1 32 2 0 100 4 33 100 94
MDCT multidetector computed tomography, T tumour stage, * T4a and b calculated together, n number of patients with histological result, TP true
positive, TN true negative, FP false positive, FN false negative, PPV positive predictive value, NPV negative predictive value
Table 4 Computed data and diagnostic performance of 64-MDCT for complete histopathological responders (ypT0N0)
n TP TN FP FN Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
ypT0N0 10 2 24 1 8 20 96 67 75 74
MDCT multidetector computed tomography, n number of patients with histological result, TP true positive, TN true negative, FP false positive, FN
false negative, PPV positive predictive value, NPV negative predictive value
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previous studies. However, the complete responder preva-
lence of the included patients (only 28.6 %) was lower
compared with published studies [22, 24, 25]. Cerfolio et
al. [25] showed a prevalence of 31 % complete responders
and an accuracy of 71 % for CT to detect complete re-
sponders when defining complete CT response as no visible
tumour. Jones et al. [22] approached CT response using East-
ern Cooperative Oncology Group criteria and dichotomised
pathological response (responder versus non-responder) with
a prevalence of 42 % responders and an accuracy of 52 %.
Other groups [21, 23, 24] used the Mandard et al. criteria [36]
to establish pathological response. They differed in the CT
approach to determine responders using, for instance, tumour
volume reduction of 50 % [21] or WHO criteria [23]. Swisher
et al. [24] assessed the maximal oesophageal wall thickness
and the relative percent change with treatment, showing that
those changes were not significant. Beer et al. [28] showed
that early changes in tumour diameter measured at the same
level, as is the case in our study, were not significant. How-
ever, in the study by Beer et al. [28] only patients with
adenocarcinoma restricted to the oesophagogastric junction
were investigated using MDCT after 14 days of chemothera-
py. We waived 3D-CT tumour volume measurements as
van Heijl et al. [47] showed that tumour volume
changes after 14 days of neoadjuvant radio-chemotherapy
as measured by 3D-MDCT were not associated with histo-
pathological tumour response.
The 74 % accuracy of predicting complete pathological
responders and the fact that assessing the pathological tu-
mour regression grade after neoadjuvant therapy with 64-
slice MDCT was correct in only 8 % show that post-
neoadjuvant therapy 64-slice MDCT cannot differentiate
pathological responders from non-responders. Moreover,
considering the high rate of overstaged complete patholog-
ical responders, we affirm that despite the high resolution of
MDCT the differentiation between viable tumour,
Fig. 3 A 66-year-old, overstaged histopathological complete respond-
er (T0 N0 M0) with squamous cell carcinoma of the middle thoracic
oesophagus. a Axial pre-neoadjuvant therapy, contrast-enhanced
MDCT obtained at the level of the right superior pulmonary vein
shows an asymmetric wall thickening of the oesophagus. b Decreased
thickening of the oesophageal wall on post-neoadjuvant therapy, axial,
contrast-enhanced MDCT image obtained at the same level. As a result
of the persistent slight wall thickening MDCT predicted stable disease
and overstaged the tumour as T1/2 disease. However, the surgical
specimen showed complete tumour regression
Table 5 Computed data and diagnostic performance of 64-MDCT for tumour regression grade
TRG n TP TN FP FN Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
TRG 1/CR 7 0 18 0 7 0 100 0 72 72
TRG 2/PR 10 0 11 4 10 0 73 0 52 44
TRG 3/SD 3 2 3 19 1 66 14 10 75 20
TRG 4+5/DP 5 0 20 0 5 0 100 0 80 80
MDCT multidetector computed tomography, TRG tumour regression grade, CR complete response, PR partial response, SD stable disease, DP
disease progression, n number of patients with histological result, TP true positive, TN true negative, FP false positive, FN false negative, PPV
positive predictive value, NPV negative predictive value
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inflammation and scar tissue after neoadjuvant therapy is
not possible using MDCT [26, 41].
Our study confirms the results of previous authors [25,
27, 48] that the ability of MDCT to differentiate between
tumours from T1 to T3 stages remains poor as the different
wall layers cannot be differentiated (sensitivity 31 %, 60 %;
specificity 59 %, 64 % for T1/T2 and T3, respectively). In
one patient with pathological T1N1 disease the tumour was
not even visible on MDCT.
With regard to the study by Cerfolio et al. [25] which
showed an accuracy of 76 % in distinguishing T4 from T1 to
T3 disease, our results with high negative predictive values
for T3 and T4 disease (80 %/100 %, respectively), although
limited by the small number of patients, tend to confirm the
trend of MDCT to be able to exclude those advanced tumour
stages with a higher likelihood. These findings are important
because MDCT is still widely applied for monitoring
neoadjuvant therapy, restaging oesophageal cancer and, in
consideration of those post-treatment MDCT results, defin-
ing the further treatment such as curative surgery or pallia-
tive methods.
Regarding the N staging, previous authors described a low
diagnostic accuracy of CT for N stage ranging between 52 and
78 %, using cut-off values between 6 and 10 mm for lymph
node diameter [21, 22, 25, 49]. Our 64-sliceMDCTstudy also
shows a low accuracy of 69 % for determining the N stage,
because it is not possible to differentiate between non-
enlarged nodal metastasis and normal lymph nodes onMDCT.
The result of our study that MDCT is of limited value for
restaging of patients with oesophageal cancer following
neoadjuvant treatment is in line with the results of the studies
which assessed the value of morphologic imaging (including
MDCT,MRI and EUS) for restaging of rectal or gastric cancer
following neoadjuvant treatment. The reason for the limited
value of MDCT in our study might be explained by the fact
that changes due to fibrosis, inflammation and residual, viable
tumour cannot be reliably distinguished [50, 51] and
micrometastasis in normal sized lymph nodes cannot be ex-
cluded by morphological imaging [52].
We acknowledge the following limitations. The first and
most important limitation is the overall small population
with only 10 of 35 patients (28.6 %) being classified as
Fig. 4 A 61-year-old patient
with histopathological T3 N0
M0 adenocarcinoma of the
middle thoracic oesophagus.
a Axial pre-neoadjuvant
therapy, contrast-enhanced
MDCT shows an enlarged right
paratracheal lymph node above
the azygos vein. b Post-
neoadjuvant therapy, contrast-
enhanced MDCT at the same
level shows a decreased, now
borderline sized 10 mm lymph
node. MDCT correctly
predicted N0 disease
Table 6 Computed data and diagnostic performance of 64-MDCT for N staging
N n TP TN FP FN Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
N0 24 19 9 2 5 79 82 90 64 80
N1 7 4 21 7 3 57 75 36 88 71
N2 1 0 33 1 1 0 97 0 97 94
N3 3 1 32 0 2 33 100 100 94 94
MDCT multidetector computed tomography, N nodal stage, n number of patients with histological result, TP true positive, TN true negative, FP
false positive, FN false negative, PPV positive predictive value, NPV negative predictive value
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complete pathological responders (ypT0N0) to neoadjuvant
therapy. Owing to the fact that only one patient had histo-
pathological T4 disease, the high sensitivity and negative
predictive value have to be interpreted with caution.
Second, considering the likelihood of asymmetric and
random tumour regression, we only observed changes in
tumour diameter at the same level, ignoring tumour diame-
ter behaviour on upper or lower levels. Despite diameter
changes due to post-treatment effects, asymmetric tumour
regression could have led to an incorrect designation of
tumour behaviour in our study. We waived defining the
maximal tumour diameter or tumour volume after therapy,
because previous studies showed that those changes on
MDCT were not significant [24, 47]. We wanted to analyse
the tumour regression by using the modified WHO/RECIST
methods [46], because they are a robust, standardised and
clinically easily applicable method to access the response to
neoadjuvant therapy with 64-slice MDCT for experienced
and less experienced radiologists alike.
Third, by only taking the maximal lymph node diameter
into consideration we missed the normal sized but patho-
logically malignant lymph node metastasis. This might have
led to an underestimation of nodal disease.
Moreover technical issues regarding the CT protocol such
as the lack of a biphasic intravenous contrast agent adminis-
tration or the use of thinner slices and reconstruction intervals
might have influenced the results. Finally, we did not use
advanced technical possibilities such as CT perfusion.
We conclude that although MDCT tends to be able to
exclude advanced tumour stages (T3, T4) with a higher
likelihood, the diagnostic accuracy of high resolution
MDCT for restaging oesophageal cancer and assessing the
response to neoadjuvant preoperative therapy has not im-
proved in comparison to older-generation CT. Therefore, the
future assessment of oesophageal tumour response to
neoadjuvant therapy should focus on combined morpholog-
ic and metabolic imaging.
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